Investment Rating - The report does not explicitly provide an investment rating for the beauty industry Core Insights - The beauty retail industry is experiencing a dichotomy of price increases and decreases, influenced by cost pressures from tariffs and varying consumer preferences for high-end and value products [4] - Anti-aging skincare is projected to grow to a market size of 85 billion yuan by 2025, with an 11% year-on-year increase, driven by scientific advancements and consumer demand for long-term efficacy [4] - The color cosmetics segment is becoming a key driver for attracting younger consumers, with a focus on experiential marketing and social engagement [6] Industry Environment - The beauty retail sector is facing contrasting pricing strategies, with brands like Elf Beauty opting for transparent price increases while others like BeautyStat are lowering prices to boost sales. Brands are also focusing on product line optimization and e-commerce partnerships to reach price-sensitive consumers [4] - The anti-aging skincare market is shifting towards systematic scientific management, with international brands focusing on cellular repair and longevity science, while domestic brands are leveraging precision intervention and synthetic biology [4] - Color cosmetics account for 21.3% of the Chinese cosmetics market and are crucial for attracting young consumers, with a significant presence in top shopping malls, particularly in East China [6] Top Brand News - During the Double 11 shopping festival, domestic brands like Pechoin and TILOWE outperformed international brands, indicating a shift in market dynamics towards local products [6][7] - Li Jiaqi's live streaming sessions have become a significant trendsetter in the beauty category, with high-efficacy products gaining popularity among consumers [8] - Marubi Biological's revenue grew by 25.51% year-on-year during the Double 11 period, attributed to its focus on R&D and a successful single-product strategy [11]

Group 1 - China has become the second-largest medical beauty market globally, with a current penetration rate of only 4.5%, indicating significant growth potential compared to other developed countries [1] - The "light medical beauty" segment is reshaping the industry ecosystem due to its core advantages of low risk, short recovery time, and high frequency [1] Group 2 - The upstream consumables and equipment sector has high barriers to entry, with a focus on the development and manufacturing of injectables, energy-based devices, and biomaterials, which are core high-margin segments of the industry [2] - From early 2024 to July 2025, 43 Class III injectable products, 2 types of botulinum toxin, and 22 types of phototherapy devices have been approved in China, indicating a significant acceleration in product approvals [2] - The market for recombinant collagen is expected to exceed 40 billion yuan in 2024 and reach 58.57 billion yuan in 2025, while the market for "童颜针" (youthful needle) is projected to grow from 500 million yuan in 2021 to 4.2 billion yuan in 2025, a 740% increase [2] Group 3 - Companies like 四环医药 (Sihuan Pharmaceutical) are rapidly rising due to their technological advantages, having developed products like "童颜针" and "少女针," which have received Class III medical device registration [3] - 四环医药 has become the only domestic company to hold compliant registrations for both "童颜针" and "少女针," and has secured exclusive agency rights for a collagen-based product in mainland China [3] Group 4 - The current market is dominated by a few companies that can consistently obtain Class III medical device certifications, creating a concentrated oligopoly [4] - In 2025, 80% of newly approved products are expected to come from companies with Class III device qualifications, leading to a market environment where small institutions are rapidly exiting [4] - The emergence of new materials like agarose and hydroxyapatite marks a shift towards ingredient diversification, while the rise of regenerative materials signifies a transition from "filling" to "tissue regeneration" [4] Group 5 - The trend is accelerating the concentration of resources towards leading companies with R&D systems, clinical teams, and compliance capabilities, indicating an irreversible trend towards specialization and compliance in the industry [5]

Core Viewpoint - The company has shown strong growth in new orders for its energy source equipment, particularly in the Asia-Pacific region, leading to double-digit year-on-year revenue growth in the third quarter of 2025 [1][2]. Group 1: Energy Source Equipment - The demand for energy source equipment in the Asia-Pacific market is robust, with new orders in Q3 showing double-digit growth [1]. - The company's energy source equipment revenue faced challenges in the first half of the year due to high interest rates and weak consumer demand in North America, but there has been a noticeable recovery in Q3 [2]. - The flagship energy source device, Alma Harmony, has received a strong market response since its global launch in March 2025, contributing to increased order volumes [2]. Group 2: Injection Fillers - The injection filler business experienced a significant growth of 218% in the first half of the year, demonstrating strong product capability and effective channel management [3]. - The company plans to enhance the promotion of Profhilo in Thailand and expand the sales of Revanesse in the UK, German-speaking regions, Australia, and New Zealand [3]. - The long-acting botulinum toxin product, DaxibotulinumtoxinA (达希斐), is set to be launched in China following approval in September 2024, which is expected to inject new growth momentum into the injection filler business [3][4]. Group 3: Market Potential - The penetration rate of botulinum toxin in China is currently below the global average, indicating significant growth potential as consumer awareness increases [3]. - The market structure differences between China and other countries highlight the potential for increased usage of botulinum toxin in the Chinese market, which is currently underdeveloped compared to hyaluronic acid [3]. - The company’s DaxibotulinumtoxinA product has shown rapid revenue growth since its approval in the U.S., with a 32% increase in revenue for the first three quarters of 2024, primarily driven by repeat purchases [4]. Group 4: Financial Projections - The company expects revenue to reach $382 million, $442 million, and $510 million for the years 2025, 2026, and 2027, respectively, with net profits projected at $29 million, $36 million, and $45 million [4]. - The earnings per share (EPS) are forecasted to be $0.06, $0.08, and $0.10 for the same years, indicating a favorable growth trajectory [4].

Core Insights - The report by KPMG highlights that China's medical aesthetics industry has reached a market size of over 100 billion RMB and is experiencing the fastest growth globally, with potential to reach 1 trillion RMB by 2030 [1] Market Demand - In 2024, over 50% of the market demand for medical aesthetics will come from Generation Z (born 1997-2012), who view these services as a form of daily self-care rather than corrective treatments [1] - There is a rising demand from male consumers for light medical aesthetic procedures such as hyaluronic acid injections, botulinum toxin, microneedling, and intense pulsed light treatments [1] Market Growth - The market size for light medical aesthetics grew from 50.2 billion RMB in 2018 to 146 billion RMB in 2023, with the number of consumers increasing from 7.4 million to 23.5 million [1] - The shift towards non-surgical procedures is significant due to their lower risks, shorter recovery times, and easier accessibility [1] Geographic Trends - Medical aesthetic demand is shifting from traditional first-tier cities like Shanghai and Beijing to emerging first and second-tier cities such as Chengdu, Chongqing, and Hangzhou, which have lower living costs and considerable disposable income [1]

Core Insights - The China medical beauty industry is rapidly rising, driven by a large market size, evolving technology, and increasing consumer demand, positioning it as a global focal point [3][4][9] - The industry is projected to reach a market size of 1 trillion RMB by 2030, with a significant shift in consumer demographics towards younger generations, particularly Generation Z [4][5][9] Market Overview - The medical beauty market in China has grown from 50.2 billion RMB in 2018 to 146 billion RMB in 2023, with the number of consumers increasing from 7.4 million to 23.5 million [5] - The demand for non-invasive procedures, such as botulinum toxin and hyaluronic acid fillers, is on the rise, particularly among younger consumers who view these treatments as part of their daily self-care routine [5][6] Consumer Demographics - Generation Z accounts for over 50% of the market demand for medical beauty services, contrasting with previous generations who viewed these services as corrective treatments [4][5] - There is a notable increase in male consumers seeking light medical beauty treatments, indicating a diversification of the consumer base [4] Growth Drivers - The growth of the medical beauty industry is supported by economic factors, with over 400 million middle-income individuals in urban areas and an aging population driving demand for anti-aging and skin repair services [6][7] - The industry is also benefiting from personalized service offerings and the adoption of advanced technologies, such as AI skin analysis tools [6] Geographic Trends - Demand for medical beauty services is expanding from traditional first-tier cities like Shanghai and Beijing to emerging second-tier cities such as Chengdu and Hangzhou, which offer lower living costs and substantial disposable income [7] Innovation and Challenges - Despite strong growth, the industry faces challenges such as safety compliance, talent shortages, and consumer retention [8] - Innovations in service models, including digital and remote consultations, are expected to drive future growth, alongside advancements in regenerative medicine [8] Future Outlook - The medical beauty industry in China is moving towards a more mature, regulated, and intelligent development phase, with opportunities for international collaboration and technology leadership [9] - The industry is anticipated to contribute to the "Healthy China 2030" strategy by enhancing domestic demand and injecting new growth momentum into the global beauty and health sector [9]

Summary of Medical Aesthetic Industry Conference Call Industry Overview - The medical aesthetic industry is experiencing a slowdown in growth, with leading chain institutions and light medical aesthetic models still maintaining growth. Single stores or non-compliant institutions are facing difficulties, and the proportion of channel medical aesthetics is decreasing [1][2][12]. Key Insights and Arguments - Revenue growth for institutions is up 6% year-on-year, with increased customer flow but a decrease in average transaction value (ATV) by approximately 6%. First-tier cities performed particularly well, with an expected annual growth rate of about 10% for chain institutions [1][2][3][4]. - Promotional activities were advanced to September, significantly boosting revenue, with the repurchase rate of existing customers rising to 61% [1][5]. - The pricing strategy varies significantly among products, with low-priced products used for customer acquisition and high-priced products maintaining profit margins. Institutions attract new customers with low initial prices, then revert to original prices for subsequent treatments [1][9][10]. - Regulatory tightening has led to reduced advertising expenditures in traditional channels, shifting focus to customer referrals and internal membership management systems, resulting in decreased marketing costs but improved ROI [1][11]. Market Dynamics - The industry is expected to focus more on profit margins rather than solely on revenue growth, with a projected overall revenue growth of less than 10% by 2026 and a potential further decline in ATV [3][25]. - The customer demographic has shifted, with a 16% year-on-year increase in customer flow in September, and a notable rise in the proportion of returning customers [5]. - High-end products like collagen and hyaluronic acid are expected to see increased procurement, while non-compliant products will be suspended [3][25]. Product Performance - Different price segments are performing well, with significant growth in customer acquisition products such as water light needles and photon rejuvenation [6][8]. - The price of some products has decreased, such as the Ningbo Weimei 4mg product, while high-end products have maintained stable pricing [8][9]. - The market for botulinum toxin has shown stable growth, with annual growth rates exceeding 10% from 2023 to 2025, despite strict regulations limiting advertising [24]. Future Trends - The industry is expected to develop more healthily and sustainably, with a focus on compliance and quality. Non-compliant small institutions may be eliminated due to increased regulatory scrutiny [12][13]. - Mergers and acquisitions are occurring, particularly among traditional institutions that have not adapted to the light medical aesthetic trend [14]. - Institutions prefer self-built stores over acquiring local existing institutions to maintain brand consistency and leverage operational advantages [15]. Conclusion - The medical aesthetic industry is navigating a complex landscape of regulatory changes, shifting consumer preferences, and competitive pressures. Institutions are adapting by refining their marketing strategies, focusing on customer retention, and optimizing product offerings to ensure sustainable growth in a challenging environment [12][30].

Financial Performance - In the first three quarters of 2025, the company achieved total revenue of approximately 4.328 billion yuan, a year-on-year increase of 0.89% [2] - Gross profit margin reached 59.35%, an increase of 1.77 percentage points compared to the same period last year [2] - Net profit attributable to shareholders was approximately 366.95 million yuan, a year-on-year increase of 0.5% [2] - Net cash flow from operating activities was approximately 359 million yuan, a year-on-year decrease of 1.87% [2] - Basic earnings per share were 2.2346 yuan, a year-on-year increase of 366.90% [2] - Total assets were approximately 8.617 billion yuan, a year-on-year increase of 5.67% [3] - Net assets attributable to shareholders were approximately 3.413 billion yuan, a year-on-year increase of 19.07% [3] Business Segment Performance - Medical beauty segment revenue was approximately 2.237 billion yuan, a year-on-year increase of 2.49% [3] - Women's clothing segment revenue was approximately 1.407 billion yuan, a year-on-year increase of 0.08% [3] - Infant and child segment revenue was approximately 674 million yuan, a year-on-year decrease of 1.58% [3] Investment Activities - The company generated investment income of approximately 970 million yuan from the disposal of part of its equity in Ruoyuchen [4] - The company acquired 67.50% of Chongqing Milan Baiyu Time Aesthetic Hospital for 92.475 million yuan, with a valuation dynamic price-earnings ratio of 13.38 times [4][5] - Performance commitments for Chongqing Time's net profit are set at no less than 9.29 million yuan, 9.89 million yuan, and 11.83 million yuan for 2025, 2026, and 2027 respectively [5] Online and Offline Sales Channels - Online sales for women's clothing reached approximately 652 million yuan, a year-on-year increase of 22.55% [9] - Online sales accounted for 46.80% of women's clothing revenue, an increase of 8.8 percentage points [9] - The company is integrating online and offline channels to enhance customer experience and increase repurchase rates [9] Inventory Management - As of September 30, 2025, the net value of women's clothing inventory was approximately 630 million yuan, a year-on-year increase of 13.84% [10] - Inventory less than one year old was approximately 522 million yuan, a year-on-year increase of 23.55% [10]

Core Viewpoint - Four Seasons Pharmaceutical (00460) saw a nearly 9% increase in stock price, reaching HKD 1.75 with a trading volume of HKD 137 million, following the approval of its product "Frozen Beauty" by the National Medical Products Administration of China [1] Group 1: Product Approval - The company announced that its subsidiary, Meiyan Space Biotechnology (Jilin) Co., Ltd., received a Class III medical device registration certificate for its self-developed injectable transparent sodium hyaluronate composite solution, branded as "Frozen Beauty" [1] - "Frozen Beauty" is the first approved product in China that contains L-carnosine, designed for temporary improvement of skin dryness and dull complexion [1] Group 2: Strategic Development - The approval of "Frozen Beauty" marks another milestone for Meiyan Space, following the earlier launches of "Youthful Needle" and "Girl Needle" within the year [1] - The company is building a strategic product matrix focused on compliant regenerative materials (Youthful Needle, Girl Needle) and skin quality management (Water Light Needle), enhancing its position in the light medical beauty sector [1] Group 3: Product Portfolio - Meiyan Space has over 30 approved products, establishing a comprehensive product layout in the light medical beauty field [1] - The company aims to provide an integrated solution from skin quality improvement to contour modification, reinforcing its leading position in comprehensive anti-aging solutions [1]

Core Viewpoint - The medical beauty market in China is experiencing a "price war," initiated by the internet medical beauty platform New Oxygen, which has significantly reduced the price of its "Miracle Youth 3.0" product to 2999 yuan, aiming to disrupt the high-price cycle in the industry [1][3]. Group 1: Market Dynamics - New Oxygen's price reduction strategy is intended to shift the medical beauty industry from a "seller's market" to a "mass consumer" market, making compliant medical beauty services more accessible to consumers [1][5]. - The market for "Youthful Needle" treatments is rapidly expanding, with projections indicating that the B-end market size will reach 4.2 billion yuan by 2025, up from 500 million yuan in 2021 [3][4]. - The medical beauty consumer demographic is evolving, with 90% of sales now coming from working and middle-class women, indicating a shift towards a broader consumer base [7]. Group 2: Company Strategy - New Oxygen's CEO, Jin Xing, emphasizes that the low-price strategy is crucial for eliminating "black medical beauty" practices by making compliant services affordable [1][6]. - The company has faced challenges with suppliers due to its aggressive pricing, leading to supply disruptions and demands from manufacturers to withdraw products from the market [4][5]. - New Oxygen's offline chain business has become a significant revenue driver, with a 426.1% year-on-year increase in revenue from this segment, surpassing online business for the first time [8]. Group 3: Financial Performance - In Q2, New Oxygen reported a 7% year-on-year decline in overall revenue to 379 million yuan, with a net loss of 36 million yuan, attributed to a decrease in the number of medical service providers on its subscription platform [1][8]. - The company's gross margin for its chain clinics was 24.3%, significantly lower than the industry average of over 50%, reflecting its low-margin strategy aimed at fostering a healthier operational model [5][6]. Group 4: Future Outlook - New Oxygen is actively working on supply chain integration by acquiring and representing key equipment and products, indicating a strategic move to gain control over its supply chain [9]. - The company plans to develop its own brand of medical beauty products, which will be used internally and sold to other institutions, further expanding its market presence [9].

Core Viewpoint - The internet medical beauty platform, New Oxygen, has launched its new "Miracle Youth 3.0" at a price of 2999 yuan, significantly lower than the previous market average of over 10,000 yuan, aiming to disrupt the high-price cycle in the medical beauty industry [1][4]. Group 1: Pricing Strategy and Market Position - New Oxygen's price reduction strategy is intended to shift the medical beauty industry from a "seller's market" to a "mass consumer" market, making compliant medical beauty services more accessible [1][5]. - The CEO of New Oxygen, Jin Xing, believes that lowering prices is crucial to eliminate "black medical beauty" practices in China, as high prices drive consumers to seek unregulated services [6][7]. - The company aims to achieve a healthy operational model in the medical beauty industry by demonstrating that high profits are not necessary for sustainability [5][6]. Group 2: Market Growth and Potential - The market for "youthful needles" is rapidly expanding, with projections indicating that the B-end market size will reach 4.2 billion yuan by 2025, up from 500 million yuan in 2021 [4]. - New Oxygen's focus on "youthful needles" is based on their clear treatment principles and effective results, positioning it as a long-term growth area in the medical beauty sector [4][5]. Group 3: Business Transformation and Challenges - New Oxygen's offline chain business has become a significant revenue source, with a 426.1% year-on-year increase in revenue from this segment, surpassing online business for the first time [8]. - Despite the growth in offline business, the company faced a 7% decline in overall revenue in Q2, resulting in a net loss of 36 million yuan, attributed to a decrease in the number of medical service providers on its subscription platform [1][8]. - The company is actively working to reduce its reliance on suppliers by customizing products and exploring the development of its own medical beauty brand [9].